Background: Women with gynecologic cancer are at higher risk of venous thromboembolism (VTE) due to malignancy, pelvic surgery, increased age, and frequently comorbidities. The rate of VTE among different gynecologic cancers and relative to benign gynecologic surgeries has not been reported in a nationally representative cohort. Methods: Using the American College of Surgeons National Surgical Quality Improvement Program database, gynecologic surgeries were identified retrospectively from 2006 to 2012. Clinical characteristics, surgical procedures, and 30-day postoperative complications were abstracted. Multivariable logistic regression models were performed. Results: Of all gynecologic surgeries (n = 104,368), 11,427 were performed for malignancy: 2.7% (n = 2800) for ovarian cancer, 6.8% (n = 7114) for uterine cancer, 1.0% (n = 1026) for cervical cancer, and 0.5%(n = 487) for vulvar cancer. 202 (1.8%) patients experienced a VTE. Ovarian cancer had a deep venous thrombosis and pulmonary embolism rates of 1.6% and 1.5% compared with uterine cancer, 0.8% and 0.8%, respectively. Ovarian cancer patients were 1.8 (95% confidence interval [CI], 1.19Y2.65) times more likely to have a deep venous thrombosis and 1.7 (95% CI, 1.11Y2.51) times more likely to have a pulmonary embolism than patients with uterine cancer. Compared with all gynecologic cancer surgeries, ovarian cancer patients were 1.5 times more likely to have a VTE (95% CI, 1.10Y2.16). Patients undergoing minimally invasive surgery were 64% less likely to have a VTE regardless of malignancy site; however, if they had disseminated disease, they remained at higher risk of VTE (odds ratio, 5.96; P = 0.027). Conclusions: Of gynecologic cancer surgeries, ovarian cancer patients had the highest rate of VTE. Venous thromboembolism rates were lower in those who had minimally invasive surgery but remained higher in those with disseminated disease.
V enous thromboembolism (VTE) occurs in the general population with an estimated incidence of 1 to 2 per 1000 in the United States with 50% of patients experiencing long-term complications such as swelling, pain, discoloration, and scaling in the affected limb. 1 Venous thromboembolism can potentially be a life-threatening complication. It is well known that patients with malignancies are at an increased risk of VTE. 2, 3 This in part is due to Virchow triad of hypercoagulability, stasis, and endothelial injury, which forms the basis of understanding of the pathophysiology of VTE. It is established that VTEs occur more frequently in surgical oncologic patients. 4, 5 Cancer patients are at an elevated risk of VTE due to a myriad of factors, including endothelial injury secondary to tumor burden, prolonged central intravenous access, surgical trauma, chemotherapeutic agents, radiation, and relative immobility. Studies have reported varying incidences of VTE based on type of malignancy. Tateo et al 6 found the rate of VTE in epithelial ovarian cancer patients to be 16.6% in a single institutional study. Peedicayil et al 7 also reported a single institution's incidence of VTE of 4% within all gynecologic cancer patients. However, large population-based data and more descriptive analyses have been limited. Furthermore, a distinctive working group consisting of the Division of Blood Diseases and Resources, National Heart, Lung, and Blood Institute, and the National Cancer Institute met in August 2014 and determined the major areas of unmet needs in the field of cancer-related thrombosis. They believed more research was needed in the appropriate selection of cancer patients to receive thromboprophylaxis in the inpatient and outpatient settings. 8 The current study was designed to help gynecologic surgeons identify patients at increased risk of VTE by defining the incidence and the comparative risk of VTE among gynecologic cancers of different primary sites and surgical modalities.
MATERIALS AND METHODS
After obtaining the University of Pennsylvania Institutional Review Board approval (IRB no. 820313), gynecologic surgeries performed between 2006 and 2012 were identified using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database. The ACS-NSQIP is a nationally validated, risk-adjusted, outcomesbased program that captures and reports 30-day morbidity and mortality outcomes for all major inpatient and outpatient surgical procedures from across the nation. Data were collected by trained surgical clinical reviewers provided by the ACS. Perioperative outcomes within NSQIP have been validated by the trained surgical clinical reviewers of individual patient charts per standard registry protocols. Pulmonary embolism (PE) was determined by the following: V-Q scan (interpreted as high probability of PE), a positive computed tomography (CT) examination, transesophageal echocardiogram, pulmonary arteriogram, CT angiogram, or any other definitive modality. Deep venous thrombosis (DVT) was diagnosed by duplex ultrasound, venogram, or CT scan. 9 Inclusion criteria included any patient who had surgery for gynecologic malignancy. These cases were identified using The primary outcome of the study was the occurrence of VTE by malignancy site, which was further subcategorized as PE, DVT, or both within 30 days postoperatively. In addition, subset analyses of VTE risk in patients undergoing minimally invasive surgery (MIS) were performed. Disseminated disease was used as a surrogate for advanced cancer and was also evaluated for risk of VTE. Disseminated disease was defined by the NSQIP database as cancer that (1) has spread to 1 site or more sites in addition to the primary site and (2) in whom the presence of multiple metastases indicates the cancer is widespread, fulminant, or near terminal.
Means, standard deviations, percentages, and interquartile ranges (IQRs) were computed to describe continuous and categorical variables; W 2 and multivariable logistic regressions were used to assess the association of potential risk factors for VTE according to the primary gynecologic cancer site. Odds ratios (ORs) and 95% confidence intervals (CIs) were reported. Stata/ MP 13.0 was used for analysis. A 2-sided P = 0.05 was considered statistically significant.
RESULTS
A total of 104,368 gynecologic surgeries were identified, and a total of 0.53% (n = 492) of these patients developed VTE. Specifically, 242 patients (0.23%) had a DVT, and 299 patients (0.29%) had a PE. Forty-nine patients with a diagnosis of PE also had a diagnosed DVT.
Of all gynecologic surgeries, 10.9% (n = 11,427) were performed with a diagnosis of gynecologic malignancy. Patient characteristics are shown in Table 1 . Within gynecologic cancer surgeries, 24.5% (n = 2800) were performed for ovarian cancer, 62.3% (n = 7114) for uterine cancer, 9.0% (n = 1026) for cervical cancer, and 4.3% (n = 487) for vulvar cancer. The overall median age was 61 years (IQR, 53Y69 years) for women who underwent gynecologic cancer surgery, and the median BMI was 30.2 mg/kg 2 (IQR, 25.0Y37.3 mg/kg 2 ). The majority of patients were white (76.5%, n = 8732), and just over half had 1 or more comorbidities (55.5%, n = 6343). Demographic features differed among the various types of gynecologic cancer. Notably, cervical cancer patients were significantly younger TABLE 1. Characteristics of patients undergoing surgery for gynecologic malignancy using the NSQIP database For gynecologic cancer surgeries (n = 11,427), the overall frequency of VTE was 1.8 %(n = 202), which was higher than that seen in all gynecologic surgery (n = 92,941) with a VTE frequency of 0.53% (n = 492). Among gynecologic cancers, VTE was more frequently seen in patients undergoing ovarian cancer surgeries (3.0% P G 0.0001) versus those with uterine cancer (1.4%), for cervical cancer (1.5%), and for vulvar cancer (1.2%). The rate of VTE in those patients who underwent lymph node dissection (n = 4688) was 1.9%, which is similar to the overall rate of VTE in the entire cohort. The overall frequency of DVT was 0.96%, and PE was 0.98%. With emergence of VTE prophylaxis guidelines, the rate of VTE decreased over time, from 9.1% in 2006 to 1.8% in 2012 (Table 2 ). There was an overall mortality rate of 4% (n = 8) within those with a diagnosis of VTE (n = 202); however, the cause of death was not documented by the NSQIP database.
After adjusting for race, age, BMI, ascites, comorbidities, major complications, operative time, upper abdominal surgery, and lymph node dissection, the adjusted risk of VTE remained statistically higher for those undergoing ovarian cancer surgeries. Ovarian cancer patients were found to be 1.8 (95% CI, 1.19Y2.65) times more likely to have a DVT and 1.7 (95% CI, 1.11Y2.51) times more likely to have a PE than uterine cancer patients. Compared with all patients with other types of gynecologic cancer, ovarian cancer patients were 1.5 times more likely to have a diagnosis of VTE (95% CI, 1.10Y2.16).
We sought to consider advanced intra-abdominal disease by applying the surrogate variable, disseminated disease, which consisted of 8.0% of the entire cohort (n = 913). After adjusting for disseminated disease within the entire gynecologic cancer cohort, disseminated disease (OR, 1.55; 95% CI, 1.03Y2.34) was another overall risk factor for VTE diagnosis (Table 3) .
Minimally invasive surgery was performed in 37.7% (n = 4304) of all gynecologic cancer surgeries; 6.7% (n = 187) were performed for ovarian cancer, and 52.8% (n = 3755) for uterine cancer. When controlling for MIS, ovarian cancer was not associated with an increased risk of VTE. Overall, those who underwent MIS were 66% less likely to develop a VTE (OR, 0.34; P e 0.0001) ( Table 4) .When accounting for advanced cancer, disseminated disease in those undergoing MIS was present in 17.1% of patients with endometrial cancer (n = 228) and 2.3% of patients with ovarian cancer (n = 663). If patients had MIS with disseminated disease present, they had a 6 times greater likelihood of developing VTE postoperatively (OR, 5.96; 95% CI, 1.2Y29.0) ( Table 5 ).
DISCUSSION
For women undergoing gynecologic cancer surgery, ovarian cancer surgery appears to have the highest risk of postoperative VTE. Using the ACS National Surgical Database, we found that ovarian cancer patients had 1.5 times the risk of VTE compared with other gynecologic cancer patients. This risk is evident in patients who undergo open abdominal procedures. This is further illustrated by the decreased risk of VTE for patients who underwent MIS surgery, regardless of the primary site of malignancy. To date, there have been multiple studies in the general surgical and medical literature regarding risk factors for VTE, rates of VTE, and medical treatments associated with incident VTE. 10 However, this study is one of the first to capture and differentiate VTE rates among women undergoing surgery for different types of gynecologic cancers and via different modalities.
Currently, VTE prophylaxis guidelines are applied to all women undergoing surgery for gynecologic cancers undergoing an open procedure. All women with malignancy are considered at high risk of VTE regardless of tumor site. Furthermore, guidelines are not cohesive in regard to VTE prophylaxis for MIS. Our results suggest that gynecologic cancer patients are at potentially different risk of development of VTE depending on cancer type, as well as modality Therefore, preoperative and postoperative VTE prophylaxis and postoperative treatment of gynecologic malignancy may benefit from adjusting guidelines based on the specific site of neoplasm and surgical procedure performed. Postoperative prophylaxis for open abdominal procedures is supported by these data; moreover, those who undergo MIS may benefit from less extended prophylaxis. Controlled studies would be needed to test these hypotheses.
Literature regarding VTE prophylaxis is widely comparable. The American Society of Clinical Oncology (ASCO) in 2007 suggested that all hospitalized cancer patients be given anticoagulation, as well as those undergoing major surgery for malignant disease. 11 Furthermore, the National Comprehensive Cancer Network in 2006 shared similar recommendations with the ASCO guidelines. 12 Following publication of the ASCO and National Comprehensive Cancer Network guidelines, 2 prospective studies conducted in multi-institutional cohorts have suggested administering prolonged anticoagulation for surgical oncologic patients for up to 4 weeks postoperatively. They included patients who underwent major abdominal and pelvic surgery, who had residual malignant disease, obesity, and previous history of VTE. Extended prophylactic anticoagulation resulted in a 55% to 60% reduction of DVT. 13, 14 With these studies in mind, the CHEST guidelines in 2008 recommended against prophylaxis for laparoscopic procedures unless additional VTE risk factors are present. Furthermore, if open oncologic surgery was performed, they suggested continuing pharmacologic prophylaxis for 28 days after discharge. 15 The CHEST guidelines were confirmed in 2012 and recommended, with grade 1B evidence, extended-duration pharmacologic prophylaxis (4 weeks) with low-molecular-weight heparin in patients undergoing abdominal or pelvic surgery for cancer. 16 There remains some uncertainty of how to apply these guidelines among patients with different gynecologic cancers who will undergo different types of gynecologic surgery. Prior studies have shown that VTEs by the origin of malignancy have varied widely. Tateo et al 6 found a VTE risk of 16.6% in patients with ovarian cancer. Other authors reported the risk of VTE within ovarian cancers ranging from 1.2% to 5.2%.
17Y19 These studies only investigated the rate of perioperative VTE for ovarian cancer patients but never compared this risk to that for patients with other sites of disease undergoing surgery. Morimoto et al 20 evaluated 750 patients in a university hospital with gynecologic malignancies and found ovarian cancer patients to have VTE more frequently than other sites of malignancy at 4.5%.
We have found an overall incidence of VTE within ovarian cancer surgical patients to be 3.0%, with roughly equal incidences of PE and DVT (1.5% and 1.6%, respectively). In addition, VTE rates were 1.4% for uterine cancer, 1.5% for cervical cancer, and 1.2% for vulvar cancer. The rate of VTE within ovarian cancer was similar to the historic rates in the literature. However, the rate of VTE for other gynecologic cancers has been infrequently reported as 0% to 2.8% secondary to small sample size or limited documentation. 20, 21 As previously stated, current guidelines refrain from making concrete recommendations for VTE prophylaxis for any laparoscopic surgery. This stems from the low rate of VTE that has been found in past literature. Bouchard-Fortier et al 22 found that in 352 patients who did not receive any VTE prophylaxis (anticoagulation or compression devices) and underwent MIS for gynecologic cancer, only 2 patients developed a VTE (0.57%). Overall, it has been found that the rate of VTE in women with a gynecologic malignancy undergoing MIS ranges from 0.5% to 1.2%. 23Y25 Our data support that VTE risk is significantly lower in patients undergoing MIS. However, it is pertinent to note that our data suggest that not all laparoscopic We acknowledge that there are limitations of this study including its retrospective nature, although data were prospectively collected by the ACS. The NSQIP database is a nationwide collection and represents the largest data set of this kind; however, it accounts for only a fraction of patients undergoing gynecologic cancer surgeries in the United States. Given its large size and patient characteristics, we believe it to be representative of national practices and therefore relevant. Another limitation was the lack of information regarding type of VTE prophylaxis used perioperatively. Third, it is possible that uptake of VTE prophylaxis may have lagged behind recommended guidelines, and guidelines have been updated over time, for example, the 2012 (CHEST guidelines). Notably, we found a downward trend in the incidence of VTE from 2006 to 2012, which may reflect the gradual implementation of VTE prophylaxis by surgeons. In addition, we acknowledge that NSQIP is limited to 30-day postoperative data. However, most VTEs are known to occur in this immediate postoperative period. The NSQIP also lacks pathology information such as stage or histology. However, we used surrogate variables, such as disseminated disease and lymph node dissection, to adjust for extent of malignancy. Lastly, the sample size of patients who underwent MIS for disseminated ovarian cancer was small, but remained sufficient to perform the multivariable analysis.
CONCLUSIONS
We have found an overall incidence of VTE in gynecologic oncology surgery to be relatively low at 1.8% with a low mortality rate of 4%. Of gynecologic cancer surgeries, ovarian cancer patients had the highest rate of VTE. Most ovarian cancer patients undergo open surgical procedures, which were found to have a higher risk of VTE. If ovarian cancer patients had disseminated disease and underwent MIS, they remained at higher risk of VTE. However, overall VTE rates were significantly lower with MIS. It may be warranted to extend postoperative prophylactic anticoagulation to all ovarian cancer patients, as well as those who undergo MIS with disseminated disease, which has not been previously suggested. We further suggest that routine MIS patients remain at a lower risk of VTE and do not warrant extended VTE prophylaxis. Further research is needed to compare current institutional protocols and rates of VTE to further determine the need for extended prophylaxis in these subpopulations.
